Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle Factors
Launched by LUKAS VANEK · Nov 6, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain genetic features of endometrial cancer (EC) relate to lifestyle factors like obesity, high blood pressure, and diabetes. The researchers want to understand how these factors might influence the risk of the cancer coming back after treatment. By analyzing the genetic makeup of the cancer and comparing it to these lifestyle factors, they hope to find important information that could help doctors make better treatment decisions and improve patients' quality of life.
To participate in this trial, you need to have been diagnosed with endometrial cancer and have undergone surgery to remove the uterus. There are no specific exclusions for the study, so if you meet these criteria, you may be eligible. Participants can expect to provide information about their lifestyle and undergo genetic testing. This research is important because understanding the connections between genetics and lifestyle could lead to better prevention strategies and treatment options for women facing endometrial cancer.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of endometrial cancer.
- • Treated with uterine removal with adequate staging.
- Exclusion Criteria:
- • There are no exclusion criteria in this study.
About Lukas Vanek
Lukas Vanek is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in the healthcare industry, Mr. Vanek leads initiatives that focus on innovative therapeutic solutions and rigorous scientific methodologies. His approach emphasizes collaboration with leading research institutions and regulatory bodies to ensure compliance and excellence throughout the clinical trial process. By fostering an environment of transparency and integrity, Lukas Vanek aims to contribute meaningfully to the development of safe and effective treatments for diverse medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Praha, , Czechia
Patients applied
Trial Officials
Michael Halaška, prof. MUDr.
Principal Investigator
Medical director
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported